News

 

 

 

 

 

January 2012

 

Crossbeta Biosciences, Good Biomarker Sciences and U-Protein Express join forces to develop Alzheimer’s disease biomarker with a grant from IPC-BioFarmind.

 

Three Dutch biotech companies with complementary activities and expertise announced today that they will collaborate to develop a biomarker assay for Alzheimer’s disease. This initiative is awarded with a grant from IPC-BioFarmind. Read the full press release.

 

December 2011

  

Understand what we are doing in two minutes: have a look at a short presentation by our CEO Guus Scheefhals.

 

The clip for Partners

The clip for Investors

  

December 2011

 

Crossbeta welcomes Professor Philip Scheltens, MD, PhD, internationally renowned Alzheimer researcher and Director of the Alzheimer Centre, VU University Medical Center Amsterdam, as scientific advisor.

 

For more information, go to scientific advisors

 

August 2011

Crossbeta Biosciences receives EuroTrans-Bio Grant of Eur 0.75 million.

August 28, 2011 - Utrecht, The Netherlands

Crossbeta Biosciences announced today that it has received a Grant of Eur 0.75 million for its lead program in Alzheimer’s Disease. The Grant was awarded by EuroTrans-Bio ... read more

December 2010

Crossbeta celebrates 5 year anniversary and extends laboratory capacity at Utrecht location.

December 2, 2010 - Utrecht, The Nederlands

Op 2 december viert Crossbeta Biosciences haar vijfjarig bestaan en opent bij die gelegenheid een uitbreiding van de laboratoriumcapaciteit in ... read more

April 2010

Crossbeta Biosciences completes financing round and appoints Guus Scheefhals as CEO
April 12, 2010 – Utrecht, The Netherlands

Today, Crossbeta Biosciences announced that it has successfully completed a financing round of up to Eur 2 million, which is funded by new as well as existing shareholders and also includes an ... read more